Friday, January 19, 2024 2:32:43 PM
Ever since the news of their "handshake" with Merck, I've been trying to raise my "sell all" good til cancel limit order, thru Fidelity, inching it upwards slowly.......Currently that is up to over 40 bucks......I hope the thing rises to long ago highs of $ 50, or more.......I can't think of a better way, to fight the massive shorting efforts........Am I wrong or crazy, with my "dream" ? If everyone owning shares, simply "held out" for "the moon" so to speak, wouldn't that thwart the shorting trend ?
Recent CCCC News
- Form 8-K - Current report • Edgar (US Regulatory) • 04/10/2026 11:17:23 AM
- C4 Therapeutics shares jump on expanded oncology collaboration with Roche • IH Market News • 04/09/2026 02:57:45 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/09/2026 11:07:35 AM
- C4 Therapeutics Expands Long-Term Partnership with Roche Through New Collaboration Agreement Focused on Discovering and Developing Degrader-Antibody Conjugates (DACs) • GlobeNewswire Inc. • 04/09/2026 10:59:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/03/2026 02:45:54 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/03/2026 02:45:44 PM
- C4 Therapeutics Announces First Patient Dosed in Phase 1b Trial of Cemsidomide in Combination with Elranatamab (ELREXFIO®) for Relapsed/Refractory Multiple Myeloma • GlobeNewswire Inc. • 03/25/2026 11:00:00 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/09/2026 08:20:02 PM
- C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 03/09/2026 08:01:00 PM
- Next-Generation Cancer Therapies Post Breakthrough Results Across Multiple Tumor Types • PR Newswire (Canada) • 03/05/2026 02:00:00 PM
- Next-Generation Cancer Therapies Post Breakthrough Results Across Multiple Tumor Types • PR Newswire (US) • 03/05/2026 02:00:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/26/2026 12:49:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/26/2026 12:09:49 PM
- C4 Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights • GlobeNewswire Inc. • 02/26/2026 12:00:00 PM
- C4 Therapeutics to Participate in Upcoming March Conferences • GlobeNewswire Inc. • 02/23/2026 12:10:00 PM
- C4 Therapeutics Announces First Patient Dosed in Phase 2 MOMENTUM Trial of Cemsidomide, an Oral IKZF1/3 Degrader, in Combination with Dexamethasone for Relapsed/Refractory Multiple Myeloma • GlobeNewswire Inc. • 02/23/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/18/2026 10:05:18 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/18/2026 10:05:11 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/18/2026 10:05:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/18/2026 10:04:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/18/2026 10:04:38 PM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 02/17/2026 06:45:15 PM
- C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 02/09/2026 09:01:00 PM
- C4 Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 • GlobeNewswire Inc. • 02/04/2026 12:00:00 PM
